Interestingly, a previous study that aimed to evaluate the role of tumor-infiltrating B cells (B-TILs) in the clinical response to HCC treatment found that this cancer was highly CD20+ B cells-enriched and that CD20 expression is elevated in tumor tissues compared to peritumoral ones [63]. The gene discussed is MS4A1; the disease is hepatocellular carcinoma.